Sign up to save your podcasts
Or
Share Johnson & Johnson News Daily
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Johnson & Johnson News Daily
Johnson & Johnson News Daily episodes
- JNJ Stock Analysis: Bullish Analyst Ratings vs Mixed Price Targets in 2026# Johnson & Johnson Stock Analysis: Q1 2026 Trading Update & Bullish Analyst Forecasts | JNJ Stock Podcast**Description:**Dive into the latest Johnson & Johnson (JNJ) stock analysis with comprehensive trading data and analyst insights for 2026. In this episode, we break down JNJ's current trading price of $243.86, recent price action between $240.51-$244.21, and below-average trading volume of 7.22 million shares indicating cautious market sentiment.Discover why top-tier analysts are bullish on Johnson & Johnson stock, with HSBC setting a $280 price target, Citigroup at $274, and RBC Capital maintaining an Outperform rating at $255. Learn about JNJ's impressive 2026 guidance of $99.5-100 billion in operational sales, beating consensus expectations through strong Innovative Medicine and MedTech segment growth.This podcast episode covers:- Real-time JNJ stock trading metrics and volume analysis- Multiple analyst rating upgrades from HSBC, Citigroup, and Barclays- Johnson & Johnson's $584 billion market cap positioning- Attractive 2.14% dividend yield for income investors- Long-term price forecasts through 2030, projecting potential upside to $320- Comprehensive fundamental analysis of JNJ's business segmentsPerfect for dividend investors, healthcare stock enthusiasts, and those seeking defensive blue-chip investment opportunities. Subscribe for regular stock market updates and analysis.#JohnsonAndJohnson #JNJStock #StockMarket #DividendStocks #HealthcareStocks #InvestingPodcast #StockAnalysis #MarketUpdate2026For more http://www.quietplease.aiStock up on these dealshttps://amzn.to/3QFpYIXThis content was created in partnership and with the help of Artificial Intelligence AI.3 min
- Johnson and Johnson Stock Analysis: Strong Dividend Yield and Analyst Consensus in 2024# Johnson & Johnson (JNJ) Stock Analysis: Strong Buy Signals, EU Drug Approval & Dividend Growth | March 2025 Market UpdateDive into the latest **Johnson & Johnson stock (JNJ)** analysis featuring the company's $579 billion market cap performance and recent positive catalysts. This episode covers:✅ **Current Trading Data**: JNJ opened at $240.39 with a solid P/E ratio of 21.75 and low volatility (beta 0.34)✅ **Major Catalyst**: European Medicines Agency approves expanded Darzalex administration for multiple myeloma patients✅ **Analyst Upgrades**: Citigroup raises price target to $274 (Buy), RBC lifts to $255 (Outperform), plus updates from Barclays and JPMorgan✅ **Consensus Rating**: Moderate Buy from 27 analysts with average target of $236.91✅ **Dividend Income**: $5.20 annual payout yielding 2.2% - making JNJ a top dividend stock for 2026✅ **Price Forecast**: CoinCodex projects potential rise to $248.72 within one monthPerfect for investors seeking **healthcare stocks**, **dividend aristocrats**, and **blue-chip investment opportunities**. Learn why analysts remain bullish on this pharmaceutical giant despite biosimilar competition risks.*Subscribe for daily stock market analysis, earnings reports, and investment insights.***Keywords**: Johnson & Johnson stock, JNJ stock analysis, dividend stocks 2025, pharmaceutical stocks, healthcare investment, stock market news, analyst ratings, buy recommendations---*A Quiet Please Studios Production | Visit QuietPlease.ai for more financial podcasts*For more http://www.quietplease.aiStock up on these dealshttps://amzn.to/3QFpYIXThis content was created in partnership and with the help of Artificial Intelligence AI.3 min
- JNJ Stock Surges on Pipeline Growth and Analyst Optimism Despite Light Trading Volume# Johnson & Johnson Stock Analysis: JNJ Trading Update & Analyst Outlook | Market Performance Review**Description:**Dive into the latest Johnson & Johnson (JNJ) stock performance and market analysis in this comprehensive episode. Currently trading at $239.24 with a slight 0.29% dip, we break down JNJ's recent market activity, trading volume trends, and what the numbers mean for investors.Discover why 27 Wall Street analysts maintain a "Moderate Buy" rating on Johnson & Johnson stock, with updated price targets from major firms including JPMorgan Chase (raised to $250), Wolfe Research ($240), and Erste Group Bank's bullish EPS forecast of $12.54 for fiscal year 2027.Learn about the catalysts driving JNJ's impressive 47.1% yearly gain, including:- Pipeline surge with new drug approvals positioning for stronger 2026 growth- Major legal win: $950 million talc punitive award overturned- Clinical breakthrough: 89% phase one response rate for erdafitinib- Strong technical position above 50-day moving average ($236.58)- Massive $577.90 billion market capitalizationWhether you're a current JNJ shareholder, considering pharmaceutical investments, or tracking blue-chip healthcare stocks, this episode delivers essential market insights and analyst perspectives on one of the healthcare sector's most influential companies.**Keywords:** Johnson & Johnson stock, JNJ stock analysis, healthcare stock investing, pharmaceutical stocks, dividend stocks, market analysis*A Quiet Please Production | Subscribe for daily stock market updates and investment insights*For more http://www.quietplease.aiStock up on these dealshttps://amzn.to/3QFpYIXThis content was created in partnership and with the help of Artificial Intelligence AI.3 min
- JNJ Stock Surges Past $240 on Strong Earnings Outlook and Bullish Analyst Upgrades# Johnson & Johnson Stock Analysis: JNJ Surges 2% with Bullish Analyst Targets | March 2026 Market Update**Podcast Episode Description:**Dive into the latest Johnson & Johnson (JNJ) stock performance analysis as shares climb to $239.93 on March 25, 2026, marking a strong 1.98% gain. This comprehensive market update covers JNJ's impressive 2% intraday surge, bullish analyst upgrades from JP Morgan, HSBC, and Royal Bank of Canada, and upcoming Q1 2026 earnings expectations.**Episode Highlights:**- **Stock Performance:** JNJ reaches $241.46 high with detailed volume analysis- **Analyst Price Targets:** Upgraded targets ranging from $250-$280, consensus at $236.91- **Earnings Preview:** April 14, 2026 earnings date with EPS forecast of $2.69- **Valuation Metrics:** $577.9B market cap, 2.17% dividend yield, forward P/E of 20.39- **Growth Forecast:** LongForecast projects $272 by April month-end- **Zacks Investment Rating:** #2 Buy rating based on positive earnings revisionsPerfect for investors tracking pharmaceutical stocks, dividend income opportunities, and large-cap healthcare investments. Get expert insights on JNJ's market position, institutional analyst sentiment, and technical trading patterns.**Keywords:** Johnson & Johnson stock, JNJ stock analysis, healthcare stocks 2026, dividend stocks, pharmaceutical investments, earnings preview, analyst upgrades, market cap stocks*A Quiet Please Studios production - Subscribe for daily market insights and stock analysis*For more http://www.quietplease.aiStock up on these dealshttps://amzn.to/3QFpYIXThis content was created in partnership and with the help of Artificial Intelligence AI.3 min
- JNJ Stock Holds Steady at $235: Analyst Upgrades Signal Continued Healthcare Strength# Johnson & Johnson (JNJ) Stock Analysis: March 2026 Performance Review | Market Update & Analyst InsightsDive into the latest Johnson & Johnson (JNJ) stock performance analysis for March 24, 2026. In this episode, we break down JNJ's closing price of $235.27, examine its impressive 31.64% year-to-date gains, and explore why analysts remain bullish on this healthcare giant.**Key Highlights Covered:**- Daily trading analysis: $235.27 close with 6.675M shares traded- Strong year-over-year performance: +18.34% annual growth- Bullish analyst upgrades from Barclays and Daiwa Securities- Market cap of $567 billion with 2.2% dividend yield- Low beta (0.20-0.34) positioning as defensive investment- DARZALEX pharmaceutical growth driving sector performance**Perfect for:** Long-term investors, dividend seekers, healthcare sector watchers, and anyone tracking blue-chip pharmaceutical stocks.Discover why Johnson & Johnson continues to appeal as a stability play in volatile markets, with consensus analyst ratings pointing to moderate buy opportunities and average price targets of $236.91.Subscribe for regular stock market updates and in-depth analysis of market-moving stocks. Visit quietplease.ai for more investment insights and market commentary.**Tags:** #JNJ #JohnsonAndJohnson #StockMarket #HealthcareStocks #DividendStocks #MarketAnalysis #InvestingPodcast #PharmaceuticalStocks #StockAnalysis2026*A Quiet Please Production - Your source for concise, data-driven market analysis*For more http://www.quietplease.aiStock up on these dealshttps://amzn.to/3QFpYIXThis content was created in partnership and with the help of Artificial Intelligence AI.3 min
- Johnson & Johnson Stock Analysis: Growth Potential Amid Pipeline Strength# Johnson & Johnson Stock Analysis: JNJ Trading at $235, Analysts Project Growth to $600 by 2040Discover the latest insights on **Johnson & Johnson (JNJ) stock performance** in this comprehensive market analysis episode. Currently trading at $235.42 per share with a massive $567.33 billion market cap, JNJ ranks as the 19th most valuable company worldwide.In this episode, we explore:✅ **Current Market Performance**: JNJ's impressive 48.2% one-year return despite recent 2.9% monthly pullback✅ **Bullish Price Targets**: Analyst projections ranging from $236-$241, with long-term forecasts reaching $600 by 2040✅ **Oncology Pipeline Expansion**: Promising metastatic castration-resistant prostate cancer trial results strengthening next-generation drug portfolio✅ **Dividend Stability**: Consistent $5.20 annual dividend yielding 2.21%, attracting major institutional investors✅ **Healthcare Innovation**: Revenue growth driven by medical technology expansion and breakthrough treatments✅ **Investment Risks**: Analysis of early-stage trial uncertainties and elevated P/E ratio (21.2 vs sector 16.6)Whether you're a healthcare sector investor, dividend income seeker, or pharmaceutical stock enthusiast, this episode provides essential **JNJ stock analysis** and market outlook insights.Subscribe for regular stock market updates and financial analysis from Quiet Please Productions.*#JohnsonAndJohnson #JNJStock #StockMarket #HealthcareStocks #DividendInvesting #PharmaceuticalStocks #InvestmentAnalysis*For more http://www.quietplease.aiStock up on these dealshttps://amzn.to/3QFpYIXThis content was created in partnership and with the help of Artificial Intelligence AI.3 min
- Johnson and Johnson Stock Analysis: Buy Signals Amid Mixed Technical Indicators# Johnson & Johnson Stock Analysis: Trading at $235.64 with Bullish Analyst Outlook | March 2026 Market UpdateDiscover the latest Johnson & Johnson (J&J) stock performance and analyst ratings in this comprehensive market update. Currently trading at $235.64 with strong institutional support, J&J shares are drawing significant attention from major Wall Street firms including HSBC, Goldman Sachs, and Morgan Stanley—all issuing buy ratings with price targets up to $280.In this episode, we analyze:- **Current stock performance**: 49.6% year-to-date gains and 29.33% six-month growth- **Analyst price targets**: Ranging from $262 to $280, suggesting continued upside potential- **Market capitalization**: $727.24 billion SGD, ranking as the world's 19th most valuable company- **Technical indicators**: RSI at 25.25 shows oversold conditions, presenting potential buying opportunities- **2026 price forecasts**: Expected trading range between $215.80 and $250.09- **Strategic positioning**: Major medical technology divestiture plans while maintaining strong pharmaceutical sales- **Institutional confidence**: 69.55% institutional ownership demonstrates strong investor backingWhether you're a long-term investor, day trader, or market enthusiast tracking healthcare stocks, this episode provides essential insights into one of the pharmaceutical industry's blue-chip leaders as it targets over $100 billion in revenue.*A Quiet Please Studios production - For more financial market analysis, visit QuietPlease.ai***Keywords**: Johnson & Johnson stock, J&J stock analysis, healthcare stocks 2026, pharmaceutical stocks, Wall Street analyst ratings, stock market podcastFor more http://www.quietplease.aiStock up on these dealshttps://amzn.to/3QFpYIXThis content was created in partnership and with the help of Artificial Intelligence AI.3 min
- JNJ Stock Rallies on FDA Approval: Analyst Upgrades Signal Healthcare Strength# Johnson & Johnson Stock Analysis: FDA Approval Drives Bullish Momentum Despite Trading Dip | JNJ Stock Update March 2024Johnson & Johnson (NYSE: JNJ) stock closed at $237.28 on March 18th, experiencing a modest 0.4% decline amid lower-than-average trading volume. This podcast episode provides comprehensive coverage of JNJ's recent market performance, including groundbreaking FDA approval news and multiple analyst upgrades.**Key highlights include:**- **Major FDA Approval:** J&J's oral psoriasis pill receives FDA clearance, with Guggenheim projecting over $8 billion in peak annual sales- **Analyst Upgrades:** Goldman Sachs reiterates buy rating with $265 price target; HSBC raises target to $280; Royal Bank of Canada and JPMorgan also increase price targets- **Bullish Sentiment Indicators:** Short interest dropped 17.55% to 18.18 million shares, suggesting positive investor outlook- **Market Fundamentals:** $571.2 billion market cap, 52-week range of $141.50-$251.71This episode examines why leading financial institutions including Barclays, Goldman Sachs, HSBC, and Royal Bank of Canada are showing increased confidence in JNJ stock, despite recent trading volume dips. Perfect for investors tracking pharmaceutical stocks, healthcare sector investments, and dividend blue-chip opportunities.Subscribe for regular stock market analysis, healthcare industry insights, and JNJ investment updates.*A Quiet Please production - Visit quietplease.ai for more financial podcasts***Keywords:** Johnson & Johnson stock, JNJ stock analysis, pharmaceutical stocks, FDA approval news, healthcare investing, stock market podcast, analyst ratings, psoriasis treatmentFor more http://www.quietplease.aiStock up on these dealshttps://amzn.to/3QFpYIXThis content was created in partnership and with the help of Artificial Intelligence AI.3 min
- Johnson and Johnson Stock Analysis: Steady Healthcare Play Amid Market Uncertainty# Johnson & Johnson Stock Analysis: Trading at $237 with Strong Market Cap and FDA Approval Boost | JNJ Stock Update 2026Dive into our comprehensive Johnson & Johnson (JNJ) stock analysis as shares trade at $237 with a robust $571 billion market cap. In this episode, we explore JNJ's current market position, including below-average trading volumes of 6.81 million shares and its position 6% below the 52-week high of $251.71.**Key highlights covered:**- Current P/E ratio of 20.61 and attractive 2.2% dividend yield for income investors- Bank of America Securities raises price target to $253 on updated revenue projections- Morgan Stanley's Overweight rating following FDA approval for Icotyde drug- Analyst consensus price target of $236.17 across 27 Wall Street firms- Year-end 2026 price forecasts suggesting 1-2% upside potential- Recent insider trading activity and technical trading rangesThis podcast episode provides essential insights for investors tracking healthcare stocks, dividend-paying equities, and defensive market plays. Whether you're a long-term investor or active trader, get the latest on JNJ's market performance, analyst ratings, and growth prospects in the pharmaceutical sector.Perfect for investors interested in: healthcare stocks, dividend investing, pharmaceutical industry analysis, FDA drug approvals, Wall Street analyst ratings, and defensive stock strategies.**Subscribe for regular stock market updates and investment analysis.***A Quiet Please Studios production | Visit QuietPlease.AI for more financial podcasts*---**Keywords:** Johnson & Johnson stock, JNJ stock analysis, healthcare stocks 2026, dividend stocks, pharmaceutical stocks, FDA approval impact, Wall Street analyst ratingsFor more http://www.quietplease.aiStock up on these dealshttps://amzn.to/3QFpYIXThis content was created in partnership and with the help of Artificial Intelligence AI.3 min
- JNJ Stock Rallies Past $240: Analyst Upgrades Signal Strong Healthcare Momentum Ahead# Johnson & Johnson (JNJ) Stock Analysis: March 2026 Market Performance & Analyst Outlook | Investment Podcast**Podcast Episode Description:**Dive deep into Johnson & Johnson (JNJ) stock performance in this comprehensive market analysis episode. We examine JNJ's recent trading activity showing the stock at $243.22 on March 16, 2026, with a massive $573.82 billion market cap, ranking it as the 19th most valuable company globally.Discover key investment insights including:- Recent price movements and trading volume analysis- Bullish analyst ratings from HSBC ($280 price target) and Citigroup ($274 target)- 52-week trading range from $146.36 to $248.56- Year-over-year market cap growth of 14.71%- Pharmaceutical sector positioning and outlook- Price forecasts and future potentialPerfect for investors, traders, and anyone interested in blue-chip pharmaceutical stocks, healthcare sector investing, and large-cap equity analysis.**Keywords:** Johnson & Johnson stock, JNJ analysis, pharmaceutical stocks, healthcare investing, stock market analysis, analyst ratings, market cap rankings, HSBC stock targets, investment podcast, stock trading volume**Subscribe for daily market updates and stock analysis.***A Quiet Please Studios Production | Visit quietplease.ai for more financial content*---*Runtime: [Insert Duration] | Category: Business & Finance, Investing*For more http://www.quietplease.aiStock up on these dealshttps://amzn.to/3QFpYIXThis content was created in partnership and with the help of Artificial Intelligence AI.3 min
About Johnson & Johnson News Daily
From the publisher's feed
Stay informed with "Johnson & Johnson News Daily," the essential podcast for tracking JNJ stock and staying updated on all things Johnson & Johnson. Our daily episodes deliver the latest news, expert insights, and valuable information on company developments, market trends, and financial performance. Whether you're an investor, industry professional, or simply interested in one of the world's leading healthcare companies, tune in to stay ahead of the curve with "Johnson & Johnson News Daily."
For more info go to https://www.quietperiodplease.com
Check out these deals https://amzn.to/3zlo77e
Also check out
https://podcasts.apple.com/us/channel/what-to-do-in-city-guides/id6615091666
This content was created in partnership and with the help of Artificial Intelligence AI.